Peptides for Longevity
Research overview of peptides studied for longevity, healthspan, and lifespan extension. Epithalon, MOTS-c, humanin, and longevity peptide evidence.
Research Overview
Longevity peptide research represents one of the most challenging areas to validate, as lifespan studies require decades in humans. Most evidence comes from animal models, cellular studies, and surrogate biomarkers of aging rather than direct longevity measurements.
Epithalon and the Khavinson bioregulators originate from the St. Petersburg Institute of Bioregulation and Gerontology, with reported effects on telomerase activation and organ-specific aging. While intriguing, most research appears in Russian/CIS literature with limited Western replication.
Mitochondrial-derived peptides (MOTS-c, humanin, SHLPs) represent an emerging field linking mitochondrial function to aging processes. These endogenously produced peptides may mediate some effects of metabolic interventions on healthspan, though therapeutic applications remain investigational.
Key Longevity Peptides
Epithalon (Epitalon)
Status: Not approved; research compound
| Research Area | Evidence Level |
|---|---|
| Telomerase activation | Low (cell studies) |
| Animal lifespan | Low (limited studies) |
| Human longevity | Very Low |
Primary research from Khavinson laboratory; limited independent replication.
MOTS-c
Status: Endogenous; research stage
| Research Area | Evidence Level |
|---|---|
| Metabolic regulation | Low-Moderate |
| Exercise mimetic | Low (preclinical) |
| Aging biomarkers | Low |
Mitochondrial-derived peptide with emerging research on metabolic aging.
Humanin
Status: Endogenous; research stage
| Research Area | Evidence Level |
|---|---|
| Neuroprotection | Low-Moderate |
| Metabolic effects | Low |
| Aging association | Low |
Correlational studies link humanin levels to longevity; causation unclear.
Bioregulators (Khavinson Peptides)
| Category | Example Peptides | Evidence |
|---|---|---|
| Thymic | Thymalin, Thymogen | Low-Moderate (Russia) |
| Pineal | Epithalon, Pinealon | Low |
| Other organ | Various | Very Low |
Evidence Challenges in Longevity Research
- Timeframe: Human lifespan studies take decades
- Surrogate markers: Telomere length, biomarkers may not predict longevity
- Species translation: Animal lifespans don’t directly predict human effects
- Publication bias: Positive results overrepresented
Proxy Endpoints Used
| Endpoint | Relevance to Longevity |
|---|---|
| Telomere length | Uncertain correlation |
| Telomerase activity | Mechanism, not outcome |
| Aging biomarkers | Surrogate, unvalidated |
| Healthspan metrics | More relevant, harder to measure |
Research Limitations
- Most longevity peptide claims exceed evidence
- No peptide has demonstrated human lifespan extension
- Bioregulator literature concentrated in single research network
- Western replication studies largely absent
- Regulatory approval status reflects evidence gaps
Honest Assessment
No peptide has been shown to extend human lifespan. Research on healthspan effects is more tractable but still limited. Claims should be evaluated against direct evidence, not theoretical mechanisms.
Peptides Studied for Longevity
Epithalon
LowEpitalon (Ala-Glu-Asp-Gly, AEDG) has produced telomere-related changes in cultured human cells, including a 2025 independent laboratory report. Those experiments do not show longer human life or safe clinical use; controlled human efficacy and exposure data remain unavailable.
Humanin
LowA 24-amino acid mitochondria-derived peptide (MDP) discovered in 2001 that shows cytoprotective effects in cell and animal studies. Human studies mostly measure endogenous humanin levels; associations with aging or disease do not show that administered humanin is beneficial or safe. HNG and colivelin are modified analogues, not interchangeable names for native humanin.
MOTS-c
LowMOTS-c is a mitochondrial-derived peptide investigated in metabolism, muscle and host-defense models. Human studies chiefly measure endogenous MOTS-c; a registered native-peptide intervention has not yet reported outcomes.
FOXO4-DRI
Very LowFOXO4-DRI is an experimental D-retro-inverso peptide studied for disruption of the FOXO4-p53 interaction and senescent-cell apoptosis. Findings come from molecular, cell, organ-culture and animal models; human treatment efficacy and safety have not been established.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.